Belladonna

drug
On this page

Also known as Atropa bella-donnaAtropa bella-donna wholeAtropa belladonnaAtropa belladonna whole floweringBelladonna total alkaloidsBelladonna wholeDeadly nightshadeDeadly nightshade whole

Summary

Belladonna (CHEMBL2108906) is a phase-3 clinical-stage unknown (ATC A03BA04); indicated across 2 conditions including breast neoplasm.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Unknown
  • ATC class: A03BA04
  • Indications: 2 conditions
  • Clinical trials: 6

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2108906
NameBelladonna
TypeUnknown
Max phase3
ATCA03BA04

Also known as: Atropa bella-donna, Atropa bella-donna whole, Atropa belladonna, Atropa belladonna whole flowering, Belladonna, Belladonna total alkaloids, Belladonna whole, Deadly nightshade, Deadly nightshade whole, BELLADONNA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
breast neoplasm3MONDO:0021100MONDO:0007254

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

PhaseTrials
PHASE46

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01150474PHASE4COMPLETEDPostoperative Belladonna and Morphine Suppositories in Vaginal Surgery
NCT01271855PHASE4COMPLETEDAssessing Maternal Post-partum Pain With Suppositories
NCT02600715PHASE4COMPLETEDReduction of Bladder Injection Pain With Belladonna Opiate Suppository
NCT02865395PHASE4TERMINATEDTiming of B and O Suppositories to Help Relieve Post-operative Bladder Spasms
NCT03332056PHASE4COMPLETEDThe Use of Belladonna and Opium Suppository in the Treatment of Postoperative Stent Pain
NCT03657407PHASE4COMPLETEDB&O for TLH Post-operative Pain and Nausea

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).